Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Net Margin (2020 - 2026)

Neuroone Medical Technologies filings provide 12 years of Net Margin readings, the most recent being 87.22% for Q1 2026.

  • On a quarterly basis, Net Margin rose 7654.0% to 87.22% in Q1 2026 year-over-year; TTM through Mar 2026 was 68.34%, a 4632.0% increase, with the full-year FY2025 number at 39.63%, up 31711.0% from a year prior.
  • Net Margin hit 87.22% in Q1 2026 for Neuroone Medical Technologies, down from 49.71% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 54.53% in Q4 2024 to a low of 8610.96% in Q2 2022.
  • Median Net Margin over the past 5 years was 342.14% (2023), compared with a mean of 1454.01%.
  • Biggest five-year swings in Net Margin: crashed -124961bps in 2022 and later surged 806028bps in 2023.
  • Neuroone Medical Technologies' Net Margin stood at 1512.29% in 2022, then skyrocketed by 77bps to 342.14% in 2023, then soared by 116bps to 54.53% in 2024, then crashed by -191bps to 49.71% in 2025, then plummeted by -75bps to 87.22% in 2026.
  • The last three reported values for Net Margin were 87.22% (Q1 2026), 49.71% (Q4 2025), and 59.08% (Q3 2025) per Business Quant data.